Recorded February 29, 2016

Sponsored by

Webinar Description:

Patient Derived Xenograft Program for Clinical Advancement. A patient derived xenograft (PDX) clinical program has been established where patients’ solid tumors are engrafted to form tumor models for conducting personalized treatment testing and translational oncology pharmacology studies. The PDX program is being employed by the global drug discovery and development community for conducting efficient high-throughput translational medicine trials across a multitude of patient tumor models including AML. Ultimately, co-clinical and matched patient PDX-directed trials are being implemented through several pharmaceutical industry and academic partnerships.

Learning Objectives:

• Introduction to PDX algorithm
• Overview of Champions Oncology PDX tumor bank
• Overview of Champions Oncology co-clinical program
• AML advancements
• CD34+ HSC derived humanized PDX models for immune therapy testing

Speaker:

Neal Goodwin, PhD

Vice President, Corporate Research Development

Champions Oncology

Neal Goodwin, PhD serves as Vice President, Corporate Research Development, for Champions Oncology. His responsibilities include development of the patient derived tumorgraft pharmacology portfolio for both the personalized oncology and translational oncology solutions. He previously served as the Director of Research and Development and the founding Program Director of JAX Cancer Services. Dr. Goodwin was the co-founder and Chief Scientific Officer of ProNAi Therapeutics, an advanced clinical trial-staged oncology therapeutics firm. He also previously served as a senior research scientist in genomic technologies at Pharmacia. Dr. Goodwin received a Ph.D. in Microbiology from The University of Montana and served a postdoctoral fellowship in functional genomics at The Jackson Laboratory with John Schimenti (now at Cornell).